| pubmed-article:19457937 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C0302592 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C0679729 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C1518578 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C1384494 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C0020823 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:19457937 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:19457937 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:19457937 | pubmed:dateCreated | 2009-8-5 | lld:pubmed |
| pubmed-article:19457937 | pubmed:abstractText | We undertook a randomized phase II trial to test whether the addition of paclitaxel (Taxol) to the cisplatin and ifosfamide (IP) combination could improve objective response (OR) rate, progression-free survival (PFS) and overall survival (OS) in patients with recurrent or metastatic cancer of the uterine cervix. | lld:pubmed |
| pubmed-article:19457937 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19457937 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19457937 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19457937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19457937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19457937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19457937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19457937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19457937 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19457937 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19457937 | pubmed:issn | 1569-8041 | lld:pubmed |
| pubmed-article:19457937 | pubmed:author | pubmed-author:DimopoulosM... | lld:pubmed |
| pubmed-article:19457937 | pubmed:author | pubmed-author:FountzilasGG | lld:pubmed |
| pubmed-article:19457937 | pubmed:author | pubmed-author:Papadimitriou... | lld:pubmed |
| pubmed-article:19457937 | pubmed:author | pubmed-author:BamiasAA | lld:pubmed |
| pubmed-article:19457937 | pubmed:author | pubmed-author:AravantinosGG | lld:pubmed |
| pubmed-article:19457937 | pubmed:author | pubmed-author:KalofonosHH | lld:pubmed |
| pubmed-article:19457937 | pubmed:author | pubmed-author:VourliGG | lld:pubmed |
| pubmed-article:19457937 | pubmed:author | pubmed-author:MountziosGG | lld:pubmed |
| pubmed-article:19457937 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19457937 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:19457937 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19457937 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19457937 | pubmed:pagination | 1362-8 | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:meshHeading | pubmed-meshheading:19457937... | lld:pubmed |
| pubmed-article:19457937 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19457937 | pubmed:articleTitle | Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. | lld:pubmed |
| pubmed-article:19457937 | pubmed:affiliation | Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece. | lld:pubmed |
| pubmed-article:19457937 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19457937 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19457937 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:19457937 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
